Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.
Also called NCT03018028
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 243 participants
- Sponsor
- Registry
-
NCT03018028
-
- Other papers using this trial's data
- Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03018028. Randomized; double masking; primary purpose treatment. Start 2017-01-10 (actual); primary completion 2018-01-09 (actual). Results posted on 2019-12-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
- Acronym
- PIONEER 9
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03018028- Content hash
8bc592c07e0f950fcf9a40ee95efc27f5cb19e894e18e4d1d33eb1b6c60b6abc